HK1193045A1 - 在癌症如骨髓增殖性腫瘤治療中的帕比司他與魯索利替尼的組合 - Google Patents

在癌症如骨髓增殖性腫瘤治療中的帕比司他與魯索利替尼的組合

Info

Publication number
HK1193045A1
HK1193045A1 HK14106672.6A HK14106672A HK1193045A1 HK 1193045 A1 HK1193045 A1 HK 1193045A1 HK 14106672 A HK14106672 A HK 14106672A HK 1193045 A1 HK1193045 A1 HK 1193045A1
Authority
HK
Hong Kong
Prior art keywords
ruxolitinib
panobinostat
cancer
treatment
combination
Prior art date
Application number
HK14106672.6A
Other languages
English (en)
Inventor
Fabienne Baffert
Thomas Radimerski
Brian Gadbaw
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357438&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1193045(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1193045A1 publication Critical patent/HK1193045A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14106672.6A 2011-06-14 2014-07-02 在癌症如骨髓增殖性腫瘤治療中的帕比司他與魯索利替尼的組合 HK1193045A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161496750P 2011-06-14 2011-06-14
US201161568717P 2011-12-09 2011-12-09
PCT/US2012/042174 WO2012174061A1 (en) 2011-06-14 2012-06-13 Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm

Publications (1)

Publication Number Publication Date
HK1193045A1 true HK1193045A1 (zh) 2014-09-12

Family

ID=47357438

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14106672.6A HK1193045A1 (zh) 2011-06-14 2014-07-02 在癌症如骨髓增殖性腫瘤治療中的帕比司他與魯索利替尼的組合

Country Status (21)

Country Link
US (2) US20140113919A1 (zh)
EP (1) EP2720696B1 (zh)
JP (1) JP6200884B2 (zh)
KR (1) KR20140056212A (zh)
CN (1) CN103608012A (zh)
AU (2) AU2012271814A1 (zh)
BR (1) BR112013032125A2 (zh)
CA (1) CA2844407A1 (zh)
CL (1) CL2013003577A1 (zh)
CO (1) CO6821954A2 (zh)
EA (1) EA027654B1 (zh)
ES (1) ES2595407T3 (zh)
GT (1) GT201300308A (zh)
HK (1) HK1193045A1 (zh)
IL (1) IL229766A (zh)
MX (1) MX344580B (zh)
NZ (1) NZ618367A (zh)
PE (1) PE20140604A1 (zh)
SG (1) SG195141A1 (zh)
WO (1) WO2012174061A1 (zh)
ZA (1) ZA201308815B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
PT3409278T (pt) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de proteína cinase heterocíclicos
EP2776037B1 (en) 2011-11-11 2019-01-09 Novartis AG Method of treating a proliferative disease
KR102091295B1 (ko) 2011-11-23 2020-03-19 어레이 바이오파마 인크. 제약 제제
RU2015121367A (ru) * 2012-11-08 2017-01-10 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний
US10335380B2 (en) 2013-05-10 2019-07-02 CNIC Fundacion Centro Nacional de Investigaciones Cardiovasculares Carlos III Compounds suitable for the treatment of myeloproliferative neoplasms as well as methods for the diagnosis/prognosis of myeloproliferative neoplasms
WO2015184087A2 (en) * 2014-05-28 2015-12-03 Institute For Myeloma & Bone Cancer Research Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
ES2874537T3 (es) * 2014-08-21 2021-11-05 Ratiopharm Gmbh Sal oxalato de ruxolitinib
JP6778112B2 (ja) * 2014-09-22 2020-10-28 国立研究開発法人科学技術振興機構 抗インフルエンザウイルス剤、及び抗インフルエンザウイルス剤のスクリーニング方法
CZ2014773A3 (cs) * 2014-11-10 2016-05-18 Zentiva, K.S. Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu
KR20180018507A (ko) 2015-04-20 2018-02-21 톨레로 파마수티컬스, 인크. 미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측
EP3298021B1 (en) 2015-05-18 2019-05-01 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs having increased bioavailability
WO2016196991A1 (en) * 2015-06-04 2016-12-08 Children's Hospital Medical Center Therapeutic targeting of myeloproliferative neoplasms by dusp1 inhibition
KR20180034538A (ko) 2015-08-03 2018-04-04 톨레로 파마수티컬스, 인크. 암의 치료를 위한 병행 요법
WO2017196261A1 (en) * 2016-05-11 2017-11-16 National University Of Singapore Jak and hdac dual-inhibitor compounds
WO2017209766A1 (en) * 2016-06-03 2017-12-07 Q3 Medical Devices Limited Stent
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
JP2021521170A (ja) * 2018-04-13 2021-08-26 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤
AU2019349652A1 (en) * 2018-09-25 2021-05-13 Impact Biomedicines, Inc. Methods of treating myeloproliferative disorders
CN116473973A (zh) * 2018-12-24 2023-07-25 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物的治疗用途及其固体药物组合物
JP2022520361A (ja) 2019-02-12 2022-03-30 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
WO2021154976A1 (en) * 2020-01-28 2021-08-05 Secura Bio, Inc. Methods of treating brain cancer with panobinostat
CN111407894B (zh) * 2020-02-21 2022-04-29 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种治疗复发/难治t细胞淋巴瘤的新型联合靶向药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
ES2611588T3 (es) 2005-12-13 2017-05-09 Incyte Holdings Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
KR20090110913A (ko) * 2007-02-15 2009-10-23 노파르티스 아게 Ｌｂｈ589와 암을 치료하기 위한 다른 치료제와의 조합물
LT3070090T (lt) * 2007-06-13 2019-06-25 Incyte Holdings Corporation Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas
CN103732226B (zh) * 2011-02-18 2016-01-06 诺瓦提斯药物公司 mTOR/JAK抑制剂组合疗法

Also Published As

Publication number Publication date
EA027654B1 (ru) 2017-08-31
CO6821954A2 (es) 2013-12-31
EP2720696A1 (en) 2014-04-23
MX2013014805A (es) 2014-01-24
NZ618367A (en) 2016-01-29
AU2017204469A1 (en) 2017-07-20
US20180085371A1 (en) 2018-03-29
KR20140056212A (ko) 2014-05-09
JP6200884B2 (ja) 2017-09-20
ES2595407T3 (es) 2016-12-29
CN103608012A (zh) 2014-02-26
SG195141A1 (en) 2013-12-30
BR112013032125A2 (pt) 2016-12-13
EP2720696B1 (en) 2016-05-25
WO2012174061A1 (en) 2012-12-20
AU2012271814A1 (en) 2013-12-12
US20140113919A1 (en) 2014-04-24
IL229766A (en) 2017-10-31
JP2014517039A (ja) 2014-07-17
PE20140604A1 (es) 2014-05-13
GT201300308A (es) 2017-09-28
ZA201308815B (en) 2014-07-30
EA201490016A1 (ru) 2014-04-30
CA2844407A1 (en) 2012-12-20
MX344580B (es) 2016-12-20
IL229766A0 (en) 2014-01-30
CL2013003577A1 (es) 2014-08-01

Similar Documents

Publication Publication Date Title
HK1193045A1 (zh) 在癌症如骨髓增殖性腫瘤治療中的帕比司他與魯索利替尼的組合
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
EP2751270A4 (en) OLIGOMER CONJUGATE COMPLEXES AND ITS USE
EP2925202A4 (en) SMOOTH AND VOLUMINOUS FABRIC
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
EP2884984A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD
HK1214552A1 (zh) 在腎損傷的受試者中用泊馬度胺治療癌症
EP2925301A4 (en) THERAPEUTIC PRODUCT AND ANTI-CANCER IMMUNOMODULATOR DHS1P PHOTODYNAMIC
HK1201301A1 (zh) 癌症中的 突變
HK1203952A1 (zh) 取代的苯並噻吩基-吡咯並三嗪及其在癌症治療中的用途
SI2872176T1 (sl) Karboranilporfirin za uporabo pri zdravljenju raka
HK1203430A1 (zh) 可用於治療炎症和癌症的二芳基磺酰胺
HUE038910T2 (hu) Profilaktikus és gyógytáp terápia
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
EP2717900A4 (en) SCAFFOLD KINASE INTERACTION BLOCKADES AND ITS USE IN CANCER TREATMENT
GB201102215D0 (en) Inventions and therapy
GB201102234D0 (en) Inventions and therapy
GB201102226D0 (en) Inventions and therapy
GB201102227D0 (en) Inventions and therapy
GB201102228D0 (en) Inventions and therapy
GB201102231D0 (en) Inventions and therapy
GB201102232D0 (en) Inventions and therapy
GB201102222D0 (en) Inventions and therapy
GB201102236D0 (en) Inventions and therapy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200611